home
portfolio
approach
team
careers
news
contact
investor portal
home
portfolio
approach
team
careers
news
contact
investor portal
Nextech Invest
Tyra Biosciences Initiates SURF301 Phase 1/2 Clinical Study and Doses First Patient with TYRA-300
Tyra Biosciences Initiates SURF301 Phase 1/2 Clinical Study and Doses First Patient with TYRA-300
Post navigation
Previous Post
Previous
PMV Pharmaceuticals to Participate in the 5th Annual Evercore ISI HealthCONx Conference
Next Post
Next
Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)